About US
Contact us
-
Novartis' Sandoz must cough up $39M after losing patent fight with Allergan and Duke UniversityLess than a week after Allergan and Duke University dropped their allegation that Novartis' Sandoz willfully infringed Duke’s patent for eyelash growth serum Latisse (bimatoprost), a federal jury in2023/4/10
-
Ahead of Pfizer buyout, Seagen's Padcev gains Keytruda combo nod in first-line bladder cancerWhile Merck & Co.’s Seagen merger wasn't fated to be, the companies’ clinical courtship in cancer has blossomed into a swift approval at the FDA. Monday, the U.S. drug regulatorblesse2023/4/10
-
Amid dispute with FDA, Akebia proposes new dosing for oral anemia drug in kidney diseaseAkebia Therapeutics isn’t giving up on its oral anemia drug vadadustat despite an FDA rejection and a partnership gone awry. Now, just as the company challenges the FDA decision, Akebia has offered t2023/4/6
-
Viatris maintains legal winning streak with yet another EpiPen antitrust victoryAs another round of EpiPen marketing litigation wraps, Mylan’s successor Viatris can chalk up another victory. Late last week, a federal court in New Yorktossedinvestors’ claims against V2023/4/6
-
Apellis Pharma and its rare disease, eyecare drugs draw takeover interest: BloombergAmid a recent streak of rare disease M&A deals in the biopharma industry, Apellis has attracted takeover interest, Bloomberg reports. The rare diseases and ophthalmology specialist is2023/4/4
-
After Johnson & Johnson loses again in bankruptcy case, it's game on for talc lawsuitsAfter Johnson & Johnson’s initial victory in its attempt to resolve talc lawsuits through a bankruptcy ploy, little has gone the way of the pharma giant. Friday, J&J took another2023/4/4
-
In $2.6B cell and gene therapy expansion, Sartorius buys viral vector specialist PolyplusAs the biopharma industry struggles with a dire shortage of viral vectors to make cell and gene therapies, contract manufacturers are busy beefing up their capabilities. In the latest exa2023/3/31
-
Biogen comes out ahead in investor lawsuit over Aduhelm disclosuresBiogen hasn’t had many wins with its failed Alzheimer’s disease drug Aduhelm, but now the company can chalk up a courtroom victory. This week, aMassachusetts federal judge dismissed an in2023/3/31
-
After Amarin's clash with Sarissa, CEO Karim Mikhail hits the exitIn the wake of a fight over board control with activist investor group Sarissa Capital, Amarin's CEO Karim Mikhail has abruptly left the drugmaker. Friday, in a SEC filing, AmarinsaidMikhail resigned2023/3/29
-
Fierce Pharma Asia—Takeda's manufacturing expansion; Leqembi's sales prospects; GSK's PrEP genericsTakeda is investing heavily in plasma-derived therapies. GlobalData expects Eisai and Biogen's Leqembi to accumulate $12.9 billion in sales through 2028.Viatris, Cipla and Aurobindo will make generic2023/3/29